Literature DB >> 25931273

Histomorphometric diagnostics of renal osteopathy in chronic dialysis patients at high risk of cardiovascular disease.

K Žamboch1, K Krejčí, J Škarda, M Tichý, I Überall, P Skýpalová, K Langová, D Stejskal, M Švesták, J Zahálková, V Ščudla, J Zadražil.   

Abstract

UNLABELLED: Chronic kidney disease-mineral and bone disorder (CKD-MBD) ranks among clinically and pathogenetically significant complications in patients with CKD. Numerous factors are involved in its development, and histomorphometric analysis of the bone tissue is still necessary for accurate diagnosis.
METHODS: The open, pilot, prospective study aimed at performing a comprehensive histomorphometric bone analysis in 26 dialysis patients and assessing the relationships of different types of CKD-MBD to selected parameters of calcium and phosphate metabolism, densitometry, activity of parathyroid glands, presence of diabetes mellitus, and duration of dialysis treatment.
RESULTS: Comparison of the histomorphometric characteristics demonstrated statistically significant correlations between the volume of bone trabeculae and s-procollagen 1 (.754) as well as s-calcitonin (.856). Similarly, there was a positive correlation between the size of tetracycline lines and volume of bone trabeculae (.705) and a strong negative correlation with the thickness of trabeculae (-.442). When assessing the serum levels of s-osteoprotegerin and serum RANKL, there was a correlation with osteoid thickness and bone trabeculae thickness. In case of s-osteoprotegerin, a statistical power was demonstrated in relation to osteoid thickness (.880); in case of s-RANKL, a statistical power was demonstrated in relation to the thickness of trabeculae (.830). When assessing the influence of dialysis duration, relationships to the volume of trabecular bone (.665) and volume of bone trabeculae (.949) were demonstrated. Finally, a relationship between s-1,25-hydroxyvitamin D and s-osteoprotegerin was observed (.739); also the relationships demonstrated were significantly lower volume of bone trabeculae in men (p = 0.067) and lower values of s-osteocalcin and s-procollagen 1 in diabetic patients (p = 0.014).
CONCLUSION: The results provide new noninvasive possibilities of CKD-MBD detection that are based on selected serum parameters of bone metabolism. Presented are possibilities of noninvasive assessment of different types of CKD-MBD using serum osteomarkers in relation to comprehensive CKD-MBD histomorphometry.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25931273     DOI: 10.1007/s11255-015-0989-x

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  15 in total

1.  Novel markers of kidney function as predictors of ESRD, cardiovascular disease, and mortality in the general population.

Authors:  Brad C Astor; Tariq Shafi; Ron C Hoogeveen; Kunihiro Matsushita; Christie M Ballantyne; Lesley A Inker; Josef Coresh
Journal:  Am J Kidney Dis       Date:  2012-02-04       Impact factor: 8.860

2.  CKD-mineral and bone disorder: core curriculum 2011.

Authors:  Ranjani N Moorthi; Sharon M Moe
Journal:  Am J Kidney Dis       Date:  2011-10-21       Impact factor: 8.860

3.  Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study.

Authors:  Marcello Tonelli; Paul Muntner; Anita Lloyd; Braden J Manns; Scott Klarenbach; Neesh Pannu; Matthew T James; Brenda R Hemmelgarn
Journal:  Lancet       Date:  2012-06-19       Impact factor: 79.321

4.  Repression of osteocyte Wnt/β-catenin signaling is an early event in the progression of renal osteodystrophy.

Authors:  Yves Sabbagh; Fabiana Giorgeti Graciolli; Stephen O'Brien; Wen Tang; Luciene Machado dos Reis; Susan Ryan; Lucy Phillips; Joseph Boulanger; Wenping Song; Christina Bracken; Shiguang Liu; Steven Ledbetter; Paul Dechow; Maria Eugenia F Canziani; Aluizio B Carvalho; Vanda Jorgetti; Rosa M A Moyses; Susan C Schiavi
Journal:  J Bone Miner Res       Date:  2012-08       Impact factor: 6.741

5.  Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD.

Authors:  James B Wetmore; Shiguang Liu; Ron Krebill; Rochelle Menard; L Darryl Quarles
Journal:  Clin J Am Soc Nephrol       Date:  2009-11-05       Impact factor: 8.237

Review 6.  Adynamic bone disease: clinical and therapeutic implications.

Authors:  João M Frazão; Patrícia Martins
Journal:  Curr Opin Nephrol Hypertens       Date:  2009-07       Impact factor: 2.894

7.  Role for alkaline phosphatase as an inducer of vascular calcification in renal failure?

Authors:  M Schoppet; C M Shanahan
Journal:  Kidney Int       Date:  2008-05       Impact factor: 10.612

8.  Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Authors:  Francesca Tentori; Margaret J Blayney; Justin M Albert; Brenda W Gillespie; Peter G Kerr; Jürgen Bommer; Eric W Young; Tadao Akizawa; Takashi Akiba; Ronald L Pisoni; Bruce M Robinson; Friedrich K Port
Journal:  Am J Kidney Dis       Date:  2008-06-02       Impact factor: 8.860

9.  National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges.

Authors:  D Bauer; J Krege; N Lane; E Leary; C Libanati; P Miller; G Myers; S Silverman; H W Vesper; D Lee; M Payette; S Randall
Journal:  Osteoporos Int       Date:  2012-07-14       Impact factor: 4.507

Review 10.  Bone turnover markers: understanding their value in clinical trials and clinical practice.

Authors:  R Civitelli; R Armamento-Villareal; N Napoli
Journal:  Osteoporos Int       Date:  2009-02-04       Impact factor: 4.507

View more
  1 in total

1.  Levels of vitamin D receptor and CYP24A1 in patients with end-stage renal disease.

Authors:  Jia-Jun Ye; Tian-Biao Zhou; Yun-Fang Zhang; Qi Wang; Yan-Yan Su; Jia-Min Tang; Hong-Yan Li
Journal:  Afr Health Sci       Date:  2016-06       Impact factor: 0.927

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.